Author Archives: Patricia Inacio PhD

Dosing Begins in Phase 1 Trial of INV-102, Potential PWS Therapy

The first healthy volunteers were dosed in a Phase 1 clinical trial evaluating Inversago Pharma‘s INV-102, a potential therapy for Prader-Willi syndrome (PWS) and other metabolic disorders. According to a company press release, the trial, underway in Canada, started dosing following a “No Objection Letter” from Health Canada.

First PWS Genome Sequencing Project Now Enrolling Participants

The Foundation for Prader-Willi Research (FPWR) is launching the first Prader-Willi syndrome (PWS) Genome Project, it announced. This project aims to unveil how variations in patients’ DNA influence the range and severity of PWS symptoms, and impacts response to different treatments. Initially, it is looking to enroll about…

Urinary Dysfunction Common Among Younger Patients

Bladder problems leading to urinary incontinence and other manifestations are common among children, adolescents and young adults with Prader-Willi syndrome (PWS), a study shows. The study, “High prevalence of lower urinary tract dysfunction in patients with Prader–Willi syndrome,” was published in the journal Neurourology and Urodynamics.